Fig. 3

Targeted therapy based on DNA panel sequencing results. (a) Frequencies of putatively targetable and therapy resistance-mediating variations within the clinically requested cohort. (b) Shown is the full spectrum of molecular alterations in all cases containing targetable and resistance-mediating variations in form of an oncoprint fig [27]. For abbreviations, compare legend to Fig. 1. (c) MRI of sGB_6 shows one region of extended hyperintensity (FLAIR) and a further region with notable contrast enhancement in T1 before starting individualized therapy. (d) After two cycles of therapy, hyperintensity (FLAIR) was clearly diminished and contrast enhancement almost completely disappeared, indicating partial response. Images were chosen on the levels of maximum lesions, as it would also be done for evaluation of the neuroradiological RANO criteria, that are standard for the evaluation of tumor treatment responses in gliomas [40]